The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Myeloma updates: TAK-079, quadruplet regimens, MRD & bone disease
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, highlights the key updates in the multiple myeloma (MM) field from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Prof. Raje specifically discusses data for the anti-CD38 monoclonal antibody mezagitamab (TAK-079), four-drug combination regimens, as well as MRD testing to assess deep responses in MM and bone disease.
